Amelioration of delayed-type hypersensitivity responses by IL-27 administration.
Interleukin (IL-) 27 is a member of the IL-12 cytokine family. Although recent analyses of WSX-1 (IL-27 receptor alpha chain)-deficient mice as well as in vitro studies using recombinant IL-27 revealed the immunosuppressive function of IL-27, in vivo role and therapeutic potential of IL-27 remain poorly elucidated. Here we investigated the effect of IL-27 administration on delayed-type hypersensitivity (DTH). While WSX-1-deficient mice showed higher DTH responses as shown by the degree of footpad swelling, administration of IL-27 significantly ameliorated the footpad swelling. Since the activation status of the draining lymph node cells were not affected by IL-27 deficiency, it was suggested that IL-27 affected the effector phase of the response. These results collectively indicate that IL-27 has a suppressive effect on activated T cells in the experimental model and also has a therapeutic potential for some diseases caused by immune disorder.
Department of Biomolecular Sciences, Division of Molecular and Cellular Immunoscience, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan.
Yoshiyuki
Y
Miyazaki
Yohei
Y
Shimanoe
Seng
S
Wang
Hiroki
H
Yoshida
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D017449:Dermatitis, Allergic Contact / Q000188:drug therapy* / Q000276:immunology; D004195:Disease Models, Animal; D007165:Immunosuppression Therapy; D016753:Interleukin-10 / Q000378:metabolism; D020381:Interleukin-17 / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D008817:Mice, Mutant Strains; D009154:Mutation; D018121:Receptors, Cytokine / Q000235:genetics; D018123:Receptors, Interleukin; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
C484747:Il27ra protein, mouse; D020381:Interleukin-17; D018121:Receptors, Cytokine; D018123:Receptors, Interleukin; D011994:Recombinant Proteins; D016753:Interleukin-10